Biomarker results from the KGOG3056/NIRVANA-R trial: Maintenance niraparib plus bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
It’s a common enough scenario in many synthesis labs: you know what starting material you have, and you know what product you need but not quite what reaction conditions will get you there. Unless you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results